Barclays
PACB icon

Barclays’s Pacific Biosciences PACB Stock Holding History

Barclays’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-390,000
Closed -$7.98M – 5446
2021
Q4 		$7.98M Sell
390,000
-240,000
-38% -$5.79M ﹤0.01% 1400
2021
Q3 		$16.1M Buy
+630,000
New +$18.7M 0.01% 979

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Barclays's PACB Position: Q1 2026 in Review

Barclays reduced its Pacific Biosciences (PACB) stake by 53% in Q1 2026, selling an estimated $447K and leaving 222,347 shares worth $293K. The position accounts for ﹤0.01% of the portfolio, ranked #3483.

Barclays first reported a position in PACB in Q2 2013 and has held it in 52 quarters since. The position peaked at $6.52M in Q4 2021. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

  • Barclays held 222,347 shares of Pacific Biosciences worth $293K as of Q1 2026.
  • Barclays sold 249,761 Pacific Biosciences shares in Q1 2026, an estimated $447K.
  • Pacific Biosciences made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3483 holding.
  • Barclays first reported a position in Pacific Biosciences in Q2 2013 and has held it in 52 quarters since.
  • Barclays's Pacific Biosciences position peaked at $6.52M in Q4 2021.
  • 229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.